Atara Biotherapeutics, Inc. (ATRA) Announces Quarterly Earnings Results
Atara Biotherapeutics, Inc. (NASDAQ:ATRA) posted its quarterly earnings results on Thursday. The biotechnology company reported ($1.02) earnings per share for the quarter, missing the consensus estimate of ($0.97) by ($0.05), Bloomberg Earnings reports.
Atara Biotherapeutics (NASDAQ:ATRA) traded down $0.20 during trading hours on Friday, hitting $13.00. 194,507 shares of the stock traded hands, compared to its average volume of 165,644. Atara Biotherapeutics has a one year low of $11.80 and a one year high of $23.00.
WARNING: “Atara Biotherapeutics, Inc. (ATRA) Announces Quarterly Earnings Results” was first posted by The Cerbat Gem and is owned by of The Cerbat Gem. If you are viewing this report on another domain, it was illegally copied and reposted in violation of U.S. & international copyright & trademark legislation. The correct version of this report can be read at https://www.thecerbatgem.com/2017/11/10/atara-biotherapeutics-inc-atra-announces-quarterly-earnings-results.html.
In related news, EVP Mitchall G. Clark sold 3,021 shares of the business’s stock in a transaction dated Wednesday, August 16th. The shares were sold at an average price of $14.33, for a total transaction of $43,290.93. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, CEO Isaac E. Ciechanover sold 4,400 shares of the business’s stock in a transaction dated Friday, October 27th. The stock was sold at an average price of $13.59, for a total transaction of $59,796.00. Following the transaction, the chief executive officer now owns 737,767 shares in the company, valued at $10,026,253.53. The disclosure for this sale can be found here. Over the last three months, insiders have sold 52,209 shares of company stock valued at $763,857. 16.20% of the stock is currently owned by insiders.
ATRA has been the subject of several research analyst reports. Canaccord Genuity reaffirmed a “buy” rating on shares of Atara Biotherapeutics in a research note on Thursday. Jefferies Group LLC reaffirmed a “buy” rating and issued a $30.00 price target on shares of Atara Biotherapeutics in a research note on Thursday, October 5th. Zacks Investment Research downgraded shares of Atara Biotherapeutics from a “buy” rating to a “hold” rating in a research note on Monday, August 28th. Goldman Sachs Group, Inc. (The) reaffirmed a “neutral” rating and issued a $20.00 price target on shares of Atara Biotherapeutics in a research note on Friday, October 6th. Finally, BidaskClub downgraded shares of Atara Biotherapeutics from a “hold” rating to a “sell” rating in a research note on Tuesday, August 22nd. Three investment analysts have rated the stock with a sell rating, two have assigned a hold rating and three have given a buy rating to the company. The company currently has a consensus rating of “Hold” and a consensus target price of $24.40.
Atara Biotherapeutics Company Profile
Atara Biotherapeutics, Inc is a clinical-stage biopharmaceutical company. The Company is focused on developing therapies for patients with severe and life-threatening diseases. The Company operates through the business of developing and commercializing therapeutics segment. The Company is focused on developing allogeneic or third-party derived antigen-specific T-cells.
Receive News & Stock Ratings for Atara Biotherapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Atara Biotherapeutics Inc. and related stocks with our FREE daily email newsletter.